Carboplatin plus cytarabine in the treatment of high-risk acute myeloblastic leukemia

Leukemia

Volumn 13, Issue 2, 1999, Pages 161-165

  Larrea, L ^a   Martinez J A ^a   Sanz, G F ^a   Martin G ^a   De La Rubia, J ^a   Jimenez C ^a   Jarque, I ^a   Cid, A ^a   Lopez A ^a   Sanz, M A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Acute myeloblastic leukemia; Carboplatin; High risk AML; Salvage therapy

Indexed keywords

ANTILEUKEMIC AGENT; CARBOPLATIN; CYTARABINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PRIORITY JOURNAL; RASH; REMISSION; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0344572866     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401278     Document Type: Article

References (34)

1. Gale RP, Foon KA, Cline MJ. Intensive chemotherapy for acute myelogenous leukemia. Ann Intern Med 1981; 94: 753-757.
2. Preisler HD, Brecher M, Browman G et al. The treatment of myelocytic leukemia in patients 30 years of age and younger. Am J Hematol 1982; 13: 189-198.
3. Preisler H, Early A, Raza A et al. Therapy of secondary acute non-lymphocytic leukemia: response to cytarabine-anthracycline therapy. Blood 1982; 60 (Suppl. 1): 152.
4. Hoyle CF, de Bastos, Wheatley K et al. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th trial. Br J Haematol 1989; 72: 45-53.
5. Gajewski JL, Ho WG, Nimmer SD et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 1989; 7: 1637-1645.
6. Michels SD, McKenna RW, Arthur DC et al. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985; 65: 1364-1372.
7. Kantarjian HM, Keating MJ, Walters RS et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4: 1748-1757.
8. Angelov L, Brandwein JM, Baker MA et al. Results of therapy for acute myeloid leukemia in first relapse. Leuk Lymphoma 1991; 6: 15-24.
9. Archimbaud E, Leblond V, Michallet M et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991; 77: 1894-1900.
10. Spadea A, Petti MC, Fazi P et al. Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia. Leukemia 1993; 7: 549-552.
11. Wagstaff AJ, Ward A, Benfield P et al. Carboplatin. A preliminary review of its pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 1989; 37: 162-190.
12. Martínez JA, Martín G, Sanz GF et al. A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. J Clin Oncol 1991; 9: 39-43.
13. Sanz MA, Sanz GF, Martínez JA et al. Carboplatin alone or in combination in high-risk acute nonlymphoblastic leukemia. Ann Oncol 1992; 3 (Suppl. 3): S39-S42.
14. Meyers FJ, Welborn J, Lewis JP et al. Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol 1989; 17: 173-178.
15. Benger AM, Browman GP, Walker IR et al. A pilot study of carboplatin augmentation therapy for patients with poor risk acute non-lymphocytic leukemia. Leukemia Res 1992; 16: 159-163.
16. Lioure B, Moreau P, Witz B et al. New association of high-dose mitoxantrone (MTX), carboplatin (CBDCA) and VP-16 as treatment for relapsed or refractory acute myelogenous leukemia (AML). Blood 1996; 88 (Suppl. 1): 215a (Abstr. 848).
17. Amadori S, Picardi A, Fazi P et al. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia. Leukemia 1996; 10: 766-788.
18. Marsh JH, Kreis W, Barile B et al. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside tetrahydrouridine, and carboplatin. Cancer Chemother Pharmacol 1993; 31: 481-484.
19. Ettinger LJ, Krailo MD, Gaynon PS et al. A phase I study of carboplatin in children with acute leukemia in bone marrow relapse. A report from the Children Cancer Group. Cancer 1993; 72: 917-922.
20. Montefusco E, Peti MC, Alimena G et al. Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia. Ann Oncol 1997; 8: 175-179.
21. Wang YF, Curtis JE, Lipton M et al. Cytosine arabinoside and cisdichlorodiammineplatinum II (cisplatin) alone and in combination: effects on acute myeloblastic leukemia blast cells in culture and in vivo. Leukemia 1991; 5: 522-527.
22. Estey E. Treatment of refractory AML. Leukemia 1996; 10: 932-936.
23. Appelbaum FR, Le Beau MM, Willman CL. Secondary leukemia. In: Shechter GP, McArthur JR (eds). Education Program. American Society of Hematology: Orlando, FL, 1996, pp 33-47.
24. Cancer and Acute Leukemia Group B. Criteria for evaluating acute leukemia for the Leukemia Group B. June 1974 modification of the 1969 criteria. Cancer and Leukemia Group B (CALGB). Scarsdale: New York, 1974.
25. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-210.
26. Boudart D, Beauplet A, Muller JY. How to determine the alanine-aminotransferase in the screening of blood donors. Vox Sang 1993; 65: 159-160.
27. Letendre L, Noel P, Tefferi A et al. Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia. Am J Clin Oncol 1995; 18: 382-384.
28. DeWitte T, Zwaan F, Hermans J et al. Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the Leukemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 1990; 74: 151-155.
29. Suton L, Leblond V, LeMaignan C et al. Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: outcome of 86 patients. Bone Marrow Transplant 1991; 7 (Suppl. 2): 39.
30. Hilbe W, Thaler J, Eisterer W et al. Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). Leukaemia Res 1994; 18: 655-658.
31. Santana VM, Mirro J, Kearns C et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992; 10: 364-370.
32. Well RJ, Gold SH, Krill CE et al. Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. Leukemia 1994; 8: 1626-1630.
33. Welborn JL, Kopecky KJ, Meyers FJ et al. Carboplatin infusion in relapsed and refractory acute myeloid leukemia - a Southwest Oncology Group trial. Leukemia 1995; 9: 1126-1129.
34. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective valuation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.